Fate Therapeutics (FATE) Equity Average (2016 - 2025)
Fate Therapeutics' Equity Average history spans 13 years, with the latest figure at $220.6 million for Q4 2025.
- For Q4 2025, Equity Average fell 35.21% year-over-year to $220.6 million; the TTM value through Dec 2025 reached $220.6 million, down 35.21%, while the annual FY2025 figure was $263.0 million, 23.46% down from the prior year.
- Equity Average reached $220.6 million in Q4 2025 per FATE's latest filing, down from $247.7 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $771.1 million in Q2 2021 to a low of $220.6 million in Q4 2025.
- Average Equity Average over 5 years is $471.9 million, with a median of $438.9 million recorded in 2023.
- Peak YoY movement for Equity Average: surged 153.15% in 2021, then crashed 35.21% in 2025.
- A 5-year view of Equity Average shows it stood at $704.6 million in 2021, then decreased by 28.9% to $501.0 million in 2022, then dropped by 23.03% to $385.6 million in 2023, then decreased by 11.69% to $340.5 million in 2024, then plummeted by 35.21% to $220.6 million in 2025.
- Per Business Quant, the three most recent readings for FATE's Equity Average are $220.6 million (Q4 2025), $247.7 million (Q3 2025), and $274.9 million (Q2 2025).